Clinical Trials Logo

Arthritis, Rheumatoid clinical trials

View clinical trials related to Arthritis, Rheumatoid.

Filter by:

NCT ID: NCT01034137 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Start date: January 2010
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with early rheumatoid arthritis. Patients will be randomized to receive either tocilizumab (8mg/kg iv every 4 weeks) plus weekly methotrexate (po in ascending doses), or tocilizumab (8mg/kg iv every 4 weeks) plus placebo, or methotrexate plus placebo. Anticipated time on study treatment is 2 years, and target sample size is 300.

NCT ID: NCT01029613 Completed - Clinical trials for Rheumatoid Arthritis

Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

Start date: December 2009
Phase: N/A
Study type: Observational

Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with wholebody MRI etc.

NCT ID: NCT01027728 Completed - Clinical trials for Rheumatoid Arthritis

Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis

CARAT-1
Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).

NCT ID: NCT01026519 Completed - Clinical trials for Rheumatoid Arthritis

A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

Start date: September 2008
Phase: Phase 1
Study type: Interventional

This is a single-dose, double-blind, placebo-controlled, parallel group safety, tolerability and pharmacodynamic study of subcutaneously (SC) administered REGN88 in rheumatoid arthritis patients who are receiving concomitant methotrexate. Four (4) parallel groups of 8 subjects each with active rheumatoid arthritis will be dosed SC.

NCT ID: NCT01023256 Completed - Clinical trials for Rheumatoid Arthritis

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

GM-CSF is considered to have a key role in the initiation and progression of arthritic inflammation. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics, and immunogenicity of multiple doses of MOR103, a human antibody to GM-CSF, in patients with active rheumatoid arthritis.

NCT ID: NCT01023100 Completed - Clinical trials for Arthritis, Rheumatoid

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study will test the palatability of several different CP-690,550 oral preparations in trained product tester healthy volunteers.

NCT ID: NCT01021735 Completed - Clinical trials for Rheumatoid Arthritis

Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

ORBIT
Start date: April 2010
Phase: Phase 4
Study type: Interventional

That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have not previously been exposed to biologic therapy.

NCT ID: NCT01017367 Completed - Clinical trials for Rheumatoid Arthritis

Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)

MDX1100-04
Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to: 1. determine the American College of Rheumatology (ACR) 20 response rate at Day 85 in subjects with active rheumatoid arthritis(RA) administered MDX 1100 with methotrexate (MTX); and 2. determine the tolerability and safety of multiple doses of MDX-1100 in combination with MTX in subjects with active RA.

NCT ID: NCT01011959 Completed - Clinical trials for Rheumatoid Arthritis

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Start date: December 2008
Phase: Phase 1
Study type: Interventional

This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.

NCT ID: NCT01010581 Completed - Clinical trials for Rheumatoid Arthritis

SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis

COMPONENT
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the efficacy, safety and pharmacokinetics of SC12267 (4SC-101, 35 mg) in combination with methotrexate in comparison to methotrexate alone in the treatment of patients suffering from Rheumatoid Arthritis.